Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.

Antimicrobial agents and chemotherapy - 1 Apr 2016

Feng Meizhen, Sachs Nancy A, Xu Min, Grobler Jay, Blair Wade, Hazuda Daria J, Miller Michael D, Lai Ming-Tain

Abstract excerpt

Doravirine (DOR), which is currently in a phase 3 clinical trial, is a novel human immunodeficiency type 1 virus (HIV-1) nonnucleoside reverse transcriptase inhibitor (NNRTI). DOR exhibits potent antiviral activity against wild-type virus and K103N, Y181C, and K103N/Y181C mutant viruses, with 50% inhibitory concentrations (IC50s) of 12, 21, 31, and 33 nM, respectively, when measured in 100% normal human serum...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to Benzoxazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclopropanes

Share to Drug Dosage Calculations

Share to Inhibitory Concentration 50

Share to Pyridones

Share to Rilpivirine

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 26833152
DOI: 10.1128/AAC.02650-15
PMCID: PMC4808216

Genes

NHS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.PMID 26833152Read ↗

Doravirine Resistance Patterns Identified Through Week 192 in the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Clinical Trials.Semantic proximity Read ↗

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance.Semantic proximity Read ↗

Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.Semantic proximity Read ↗

In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.Semantic proximity Read ↗

K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine.Semantic proximity Read ↗

K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to DoravirineSemantic proximity Read ↗

Potential Role of Doravirine for the Treatment of Patients with Transmitted Drug ResistanceSemantic proximity Read ↗

Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.Semantic proximity Read ↗

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infectionSemantic proximity Read ↗

Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.Semantic proximity Read ↗

In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.Semantic proximity Read ↗

Emerging reverse transcriptase inhibitors for HIV-1 infectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.